Aris Baras

All opinions expressed here are my own.

[Regeneron @Regeneron]

#BREAKING: Together with @Alnylam we announced promising phase 1 results for our investigational therapy for #NASH. Learn more at the link below.

[John Maraganore 🇺🇸🇬🇷🇺🇦 @JMaraganore]

Another @Alnylam RNAi Rx drug in the making! From human genetics discovery to human POC in 4 yrs. Just awesome! Great collab with @Regeneron & @RegeneronDNA!

[Shaheen Holloway @CoachSha10]

🗣🗣🗣🗣🗣🗣🗣🗣🗣

[Aris Baras @aris_baras]

@JMaraganore @Alnylam Kevin is an absolute biotech superstar. We are so privileged to partner and collaborate with him at Regeneron. On top of all that, he’s a great person. Congrats Kevin and Alnylam!

[ESPN @espn]

Joe Burrow's advice to the next generation of athletes 💯 @JoeyB

[ESPN @espn]

All three are still coaching in the playoffs 😳

[Regeneron @Regeneron]

For our efforts to develop our investigational antibody cocktail for COVID-19, we have been recognized by the @GalienFdn with the #PrixGalien 2021 Roy Vagelos Pro Bono Humanum Award for Global Health Equity. Congratulations to our team on this achievement!

[Aris Baras @aris_baras]

@gabecasis @RegeneronDNA Bravo @gabecasis. An amazing scientist and equally good story teller and communicator. Can't wait for the next 5M and the continued avalanche of discoveries. So far it's worked pretty well . . . genetics to therapeutics.

[John Maraganore 🇺🇸🇬🇷🇺🇦 @JMaraganore]

Exciting recognition of the spirit of #innovation which is so important within @alnylam and is key to our success! And congratulations to our friends at @Regeneron & @Moderna_tx on also being named to the Best Workplaces for Innovators list! #biotech

[Regeneron @Regeneron]

For the third consecutive year, we have been named as one of @FastCompany's Best Workplaces for Innovators thanks to our commitment to fostering a collaborative culture led by #science. #FCBestWorkplaces

[Regeneron @Regeneron]

Today, @NEJM published positive detailed results from a Phase 3 trial assessing the ability of our investigational antibody cocktail to prevent #COVID19 infection among household contacts of #SARSCoV2 infected individuals.

[Regeneron @Regeneron]

Aris Baras, Head of the Regeneron Genetics Center (#RGC), discusses how rare mutations in GPR75, a gene linked to body weight, may possibly protect against obesity.

[Aris Baras @aris_baras]

@skathire @Regeneron Thanks Sek. Power of genetics and "speed of science" on display. Step 1, protective genetics discovery. ✔️ Step 2, create therapeutics that mimic the genetic effects. We've got work to do. Heads down, hard at work. From COVID pandemic to obesity epidemic. Let’s go Regeneron!

[Regeneron @Regeneron]

The Regeneron Genetics Center (#RGC) published new findings in @sciencemagazine about the discovery of GPR75 gene mutations that protect against obesity.

[2Way Lacrosse @2WayLacrosse]

𝗦𝗶𝗴𝗵𝘁𝘀 & 𝗦𝗼𝘂𝗻𝗱𝘀: 𝟮𝟬𝟮𝟳 𝗕𝗹𝗮𝗰𝗸 𝗣𝗿𝗮𝗰𝘁𝗶𝗰𝗲
⠀
This group is getting ready to run the gauntlet this summer... Their strength of schedule / event line-up is off-the-charts difficult...
⠀
𝙒𝙤𝙧𝙠 𝙝𝙖𝙧𝙙. 𝙎𝙩𝙖𝙮 𝙃𝙪𝙢𝙗𝙡𝙚.
⠀
#2Wculture

[Regeneron @Regeneron]

#COVID19 news: We’re announcing new positive Phase 3 data demonstrating the effect of our investigational antibody cocktail in reducing risk of hospitalization or death, and duration of symptoms in non-hospitalized patients with COVID-19: https://t.co/drN2lVbhDj

[Regeneron @Regeneron]

#COVID19 news: Our investigational antibody cocktail was shown in vitro to successfully neutralize #SARSCoV2 variants first identified in the UK and South Africa. @Columbia Read more: https://t.co/HXGeiVeKoN

[Intellia Therapeutics @intelliatx]

Today, Intellia announced that the first patient has been treated with NTLA-2001, which we are developing as a potential single-course, curative therapy for all forms of #ATTR using #CRISPR /Cas9. Full press release here: https://t.co/Xc7gdW2nHo #transthyretinamyloidosis

[Adam Feuerstein ✡️ @adamfeuerstein]

FANTASTIC BREAKING NEWS: #Covid19 vaccine from Pfizer and BioNTech is strongly effective, early data from large trial indicate https://t.co/oCmd8D8Si6 via @matthewherper

[Aris Baras @aris_baras]

I’m proud of our #RGC and @Regeneron team and gratified to see our efforts having a real impact: #genetics is guiding the development of our late stage pipeline and enabling new targets and new medicines, like this collaborative approach to NASH with @alnylam @JMaraganore.

[Aris Baras @aris_baras]

Exciting #NASH progress, years in the making: @alnylam announced today the initiation of Ph1 dosing of the RNAi therapeutic ALN-HSD against the #RGC-discovered target HSD17B13 for the treatment of NASH. Check out their earnings presentation for more: https://t.co/98FR0814Bz